Navigation Links
Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
Date:7/1/2010

CHADDS FORD, Pa., July 1 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel.  The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

"We are optimistic that our expeditious and careful response to the FDA's requests will lead to the agency's approval of FORTESTA," said Julie McHugh, chief operating officer, Endo Pharmaceuticals. "We are committed to making this testosterone gel formula available as soon as possible and will continue to work closely with the FDA toward our goal of making this product available for the treatment of low testosterone in men."

ProStrakan Group plc submitted the NDA for FORTESTA to the FDA in April 2009, and Endo signed an agreement with ProStrakan in August 2009 to acquire exclusive U.S. rights to commercialize the testosterone 2% gel, branded variously as Tostran, Tostrex and Itnogen outside of the U.S. The principal content of the re-submission is a re-analysis of the primary variable (testosterone levels) in the original pivotal study.  This re-analysis has confirmed the reliability of the original conclusions of the study. In addition, Endo
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013   Life Technologies Corporation ... its Applied Biosystems™ 3500 Dx and 3500xL Dx Genetic ... Protection against Health Risks in Mexico ... extension of Life Technologies, capabilities to serve the clinical ... with Sanger -based solutions.  ...
(Date:5/20/2013)... LONDON , BERLIN ... Arthroscopy Devices Market to ... for Minimally Invasive Procedures to Drive Future Growth" looks ... for the six arthroscopy device market segments: arthroscopes, arthroscopy ... radio frequency systems, and arthroscopy visualization systems. The report ...
(Date:5/20/2013)... BOSTON , May 20, 2013  Rhythm announced ... study demonstrating a higher prevalence of gastroparesis symptoms among ... of these symptoms is high among patients with both ... is significantly under-diagnosed among those with the more common ... Kaplan , MD, PhD, Associate Professor of Medicine ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
... 17 Engineer/pilot/attorney Jon Roberts, PhD, has dozens of ... thwarts piracy in movie theatres, gadgets that track important ... and even an electronic matchmaker that alerts two nearby ... their match. Now, as Chairman and VP R&D ...
... , , WALTHAM, Mass., Nov. 17 ... firms for pharmaceutical and healthcare issues, finds that, driven by ... novel fast acting opioid reformulations, the cancer pain drug market ... in 2018 in the United States, France, Germany, Italy, Spain, ...
Cached Medicine Technology:When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:5/20/2013)... CA (PRWEB) May 20, 2013 ... been released to the public creating a frenzy ... access to this elite business training. WealthSpringMarketing.com's Tiffany ... as well as an exclusive bonus. , "Eben ... providing elite business training to individuals serious about ...
(Date:5/20/2013)... 21, 2013 People are so busy these ... levels are through the roof and are contributing to a ... stress could mean the difference between life and death. Speakers ... on 29 May will share valuable, practical tools people can ... the world around them for social good. , Organised by ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... May 20, 2013 According to a ... associated with medical malpractice amount to approximately $3.6 billion ... Institute for Healthcare Improvement estimated that there 15 million ... like these suggest that everyone who receives any form ... of medical malpractice. Merriam-Webster defines malpractice as “a ...
(Date:5/20/2013)... 2013 yurbuds®, maker of the sport ... announced the launch of its new Signature Series ITE ... with more signature athletes to come. Created with top ... ITE 100 is the perfect training partner for any ... features reflective, tangle-resistant Kevlar cords, premium sound quality and ...
Breaking Medicine News(10 mins):Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:yurbuds Expands Best-Selling Lines with Innovative New Products 2
... Foursome, WASHINGTON, May 6 Lung Cancer,Alliance-Nebraska (LCA-NE) ... won the Golf Digest U.S. Open Contest. John was ... He will try to break 100 at Torrey Pines, ... U.S. Open. Atkinson will compete in a foursome that,includes ...
... EDT http://www.westaim.com , CALGARY, May 6 /PRNewswire-FirstCall/ ... a.m. EDT on Tuesday, May 13, 2008 to broadcast ... will be releasing its 2008 first quarter,results on Monday, ... standard,disclosure over wire services, a news release and financial ...
... Calif., May 6 Thermage, Inc.,(Nasdaq: THRM ... the aesthetic,industry, today announced that it will present ... the Four Seasons Hotel in Las Vegas, Nevada. ... Time on Tuesday,May 13, 2008. Stephen J. Fanning, ...
... annual shareholders,meeting of Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... David R. Harvey, W. Lee,McCollum, Jai P. Nagarkatti, Avi ... G. Sear, D. Dean Spatz and Barrett A. Toan. ... Medtronic, Inc., was,elected to her first term as a ...
... among U.S. adolescents and young adults ages 14 through 21, ... at Buffalos Research Institute on Addictions (RIA). , ... national survey of its kind show problem gambling -- described ... gambling more than you intended or stealing money to gamble) ...
... and NEW YORK, May 6 U.S. Preventive ... announced,the company has selected its investment banking team, ... and Stanford Eagle to coordinate,its long term capital ... internationally., (Logo: http://www.newscom.com/cgi-bin/prnh/20080506/NETU129LOGO ), ...
Cached Medicine News:Health News:Lung Cancer Alliance Advocate Wins Golf Digest Contest 2Health News:Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend 2Health News:Estimated 750,000 problem gamblers among America's youth 2Health News:Estimated 750,000 problem gamblers among America's youth 3Health News:U.S. Preventive Medicine Announces Investment Banking Team 2
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
... Goldmann standard automatic or manual kinetic ... white/white, blue/yellow or red/white stimuli/background colors. ... classic 4-2 threshold strategy. Examination with ... (including 30-2, 24-2, and 10-2). Gray-scale/ ...
Medicine Products: